Related Experiment Video

Updated: Jan 8, 2026

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
04:32

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

12.4K

Antimicrobial resistance patterns and clinical outcomes in ventilator-associated pneumonia

Urvashi Krunalkumar Sharma1, Atit Dineshchandra Shah2

  • 1Department of Microbiology, Dr. N D Desai Faculty of Medical Science and Research, Dharmsinh Desai University, Nadiad, Gujarat, India.

Bioinformation
|December 15, 2025
PubMed

Insights

Ventilator-associated pneumonia (VAP) is a critical ICU issue. Acinetobacter baumannii, often multidrug-resistant, was the most common pathogen, contributing to a high VAP mortality rate.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Microbiology

Background:

  • Ventilator-associated pneumonia (VAP) presents significant challenges in intensive care units (ICUs).
  • High rates of morbidity, mortality, and increasing antimicrobial resistance complicate VAP management.
  • Effective infection control and antibiotic stewardship are crucial in ICU settings.

Purpose of the Study:

  • To investigate the spectrum of microbial pathogens causing VAP.
  • To determine the antimicrobial resistance patterns of isolated microorganisms.
  • To assess the clinical outcomes, including mortality, in VAP patients.

Main Methods:

  • An observational study design was employed.
  • Data were collected from 472 ventilated patients, with 321 diagnosed with VAP.
  • Microbial isolates, resistance patterns, and patient outcomes were analyzed.

Main Results:

  • The Acinetobacter baumannii complex was the predominant pathogen, identified in 33.33% of cases.
  • A high prevalence of multidrug resistance (97.01%) was observed among the isolates.
  • The overall mortality rate for VAP patients was alarmingly high at 45.79%.

Conclusions:

  • Acinetobacter baumannii is a leading cause of VAP in this tertiary care setting.
  • The extensive multidrug resistance necessitates urgent reassessment of treatment protocols.
  • Enhanced antibiotic stewardship and robust infection control measures are imperative to reduce VAP-associated mortality.
Keywords:
Bacterial pathogens in VAPantimicrobial drug susceptibilitymultidrug resistanceprognosis

More Related Videos

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

7.5K
Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.7K

Related Concept Videos

Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
879
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
698
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
726
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
756
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.4K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
2.5K